KODIAK SCIENCES INC. Additional Paid in Capital, Common Stock
KODIAK SCIENCES INC. (KOD) had Additional Paid in Capital, Common Stock of $1.74 billion as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-13
- 2026-06-30: Additional Paid in Capital, Common Stock $1.74B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.73B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.72B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.53B.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.74B 10-Q · filed 2026-08-13 |
| 2026-03-31 | $1.73B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.72B 10-Q · filed 2026-08-13 |
| 2025-09-30 | $1.53B 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.51B 10-Q · filed 2025-08-13 |
| 2025-03-31 | $1.50B 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.48B 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.47B 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.46B 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.44B 10-Q · filed 2024-05-15 |
| 2023-12-31 | $1.42B 10-K · filed 2025-03-27 |
| 2023-09-30 | $1.40B 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.38B 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.36B 10-Q · filed 2023-05-15 |
| 2022-12-31 | $1.33B 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.30B 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.28B 10-Q · filed 2022-08-09 |
| 2022-03-31 | $1.25B 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.22B 10-K · filed 2023-03-28 |
| 2021-09-30 | $1.19B 10-Q · filed 2021-11-09 |
| 2021-06-30 | $1.18B 10-Q · filed 2021-08-09 |
| 2021-03-31 | $1.16B 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.15B 10-K · filed 2022-03-01 |
| 2020-09-30 | $526.17M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $517.12M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $509.72M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $503.48M 10-K · filed 2021-03-01 |
| 2019-09-30 | $202.18M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $200.14M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $198.84M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $197.59M 10-K · filed 2020-03-16 |
| 2018-09-30 | $2.27M 10-Q · filed 2018-11-16 |
| 2017-12-31 | $584.00K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |